KTTA | tickerfilter.com

Fundamental analysis

25%

Profitability 8%

Dept financing 2%

Liquidity 58%

Performance 40%

Company vs Stock growth

N/A

3.420 1.250

-2.170 -63.45%

+ Add row to compare

Performance

5 Days

-9.92%

1 Month

-1.80%

3 Months

-57.42%

6 Months

-77.43%

1 Year

-86.71%

2 Year

-86.54%

Key data

Stock price

$1.09

P/E Ratio

0.00

DAY RANGE

$1.04 - $1.16

EPS

-$5.74

52 WEEK RANGE

$0.92 - $7.78

52 WEEK CHANGE

-$85.75

MARKET CAP

3.453 M

YIELD

N/A

SHARES OUTSTANDING

1.044 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-13-2025

BETA

-0.04

PUBLIC FLOAT

AVERAGE 10 VOLUME

$65,975

AVERAGE 30 VOLUME

$75,182

Company detail

CEO: Tiago R. Marques
Region: US
Website: pasithea.com
Employees: 3
IPO year: 2021

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Pasithea Therapeutics Corp. engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine.

Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference

-- Conference taking place on March 27-29, 2025 in New Orleans -- -- CAGLA NeauxCancer Conference is a leading global forum in oncology -- MIAMI, March 24, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced its Vice President of Business Development,

KTTA - Pasithea Therapeutics Corp.

Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference